Guidance, NICE advice and quality standards in development | Guidance

Showing 171 to 180 of 424

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]	Technology appraisal guidance	TBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]	Technology appraisal guidance	TBC
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable ID6596	Technology appraisal guidance	TBC
Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]	Technology appraisal guidance	TBC
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over ID6579	Technology appraisal guidance	TBC
ID6610 Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901)	Technology appraisal guidance	3 September 2026
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]	Technology appraisal guidance	TBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]	Technology appraisal guidance	10 September 2026
Implanting a baroreceptor stimulation device for resistant hypertension	Interventional procedures guidance	TBC
In-situ normothermic regional perfusion of the abdomen for donor livers following circulatory death	Interventional procedures guidance	TBC